Trial site
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality 200032, ChinaNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 9 trials at this site are about, from their registry records.
- Phase
- Phase 13 trials
- Phase 33 trials
- Phase 21 trial
- Phase 41 trial
- Status
- Active, not recruiting4 trials
- Not yet recruiting3 trials
- Completed1 trial
- Recruiting1 trial
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.2 trials
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.2 trials
- Ascentage Pharma Group Inc.1 trial
- CoreAalst BV1 trial
- Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology1 trial
- and 2 more
Running trials
Recruiting
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
NCT07179679· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Peng Liu, Doctor
Recruiting
A Clinical Study of TQB2029 for Injection in Subjects With Multiple Myeloma
NCT06700395· Phase 1· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Peng Liu, Doctor
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
NCT06711900· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Active, not recruiting
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06448312· Phase 3· Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.· Source
Recruiting
A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC
NCT06241846· Phase 2· MediLink Therapeutics (Suzhou) Co., Ltd.· Source
Contact: Coordinator Clinical operation director
Recruiting
INSIGHTFUL-FFR Clinical Trial
NCT05437900· Phase 4· CoreAalst BV· Source
Contact: Sofie Pardaens
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer
NCT05353257· Phase 3· Shanghai Henlius Biotech· Source
Recruiting
Durg Coated Balloon Angioplasty in Infrapopliteal Lesions
NCT05620095· Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology· Source
Contact: Zhenyu Shi
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error